BCRXBIOCRYST PHARMACEUTICALS INCvs its industry peers
A metric-by-metric comparison of BIOCRYST PHARMACEUTICALS INC against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCRXThis | $2.2B#7 | — | — | 2.5x#2 | 94.1%#3 | 396.9%#1 | 39.0%#2 | — | — | — | 8.8%#6 | — |
| ADPT | $4.6B#1 | — | 31.9x#12 | 16.5x#6 | 54.8%#5 | 62.7%#4 | -20.6%#6 | -41.6%#8 | — | — | 107.8%#1 | — |
| RLAY | $4.1B#2 | — | 4.6x#8 | 269.2x#11 | 53.4%#6 | 18.1%#7 | -1971.6%#11 | -31.1%#7 | — | — | — | — |
| TARS | $3.4B#3 | — | 9.9x#11 | 7.6x#5 | 146.7%#1 | 43.1%#6 | -15.7%#5 | -19.0%#5 | -33.0%#3 | — | 44.3%#4 | — |
| DNLI | $3.2B#4 | — | 3.8x#5 | — | — | -21.2%#9 | — | -61.4%#11 | — | — | 49.6%#3 | — |
| RVMDW | $2.8B#5 | — | 1.1x#1 | — | — | -88.5%#14 | — | -43.4%#9 | — | — | — | — |
| BEAM | $2.6B#6 | — | 2.4x#4 | 18.4x#7 | 120.0%#2 | 78.8%#3 | -274.6%#7 | -7.5%#4 | -40.5%#4 | — | -0.6%#7 | — |
| KOD | $2.1B#8 | — | 33.6x#13 | — | — | -30.5%#12 | — | -376.4%#13 | — | — | — | — |
| RXRX | $2.1B#9 | — | 2.2x#3 | 27.5x#9 | 26.9%#7 | -39.1%#13 | -867.9%#9 | -70.5%#12 | -175.2%#5 | — | -22.2%#8 | — |
| VCEL | $2.0B#10 | 83.4x#2 | 5.5x#10 | 7.4x#4 | 16.5%#10 | 59.4%#5 | 4.0%#4 | 4.5%#2 | 4.0%#2 | 7#1 | 25.7%#5 | — |
| ADMA | $2.0B#11 | 13.0x#1 | 5.0x#9 | 4.0x#3 | 19.6%#8 | -25.7%#11 | 37.5%#3 | 36.0%#1 | 32.9%#1 | 5#2 | -43.5%#9 | — |
| COAG | $1.9B#12 | — | 4.2x#7 | — | — | — | — | 0.0%#3 | — | — | — | — |
| VIR | $1.8B#13 | — | 1.8x#2 | 26.2x#8 | -7.6%#11 | 16.1%#8 | -699.2%#8 | -44.6%#10 | — | — | 105.0%#2 | — |
| NVAX | $1.7B#14 | — | — | 1.5x#1 | 64.7%#4 | 334.8%#2 | 40.3%#1 | — | — | — | — | — |
| TSHA | $1.6B#15 | — | 4.2x#6 | 166.7x#10 | 17.3%#9 | -22.1%#10 | -1130.6%#10 | -28.1%#6 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-19.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice